Journal
FUTURE MICROBIOLOGY
Volume 13, Issue 5, Pages 507-524Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2017-0270
Keywords
bacterial vaginosis; nitroimidazole; secnidazole; vaginitis
Categories
Funding
- BD Diagnostics
- Curatek Pharmaceuticals
- Viamet Pharmaceuticals
- Cidara Therapeutics
- Novadigm Therapeutics
- Exeltis USA
- Hologic
- Toltec Pharmaceuticals
- Alfa Wasserman
- StarPharma
- LabCorp of America
- Symbiomix Therapeutics, LLC
Ask authors/readers for more resources
Secnidazole is a next-generation 5-nitroimidazole approved for more than three decades in Europe, Asia, South America and Africa and recently in the USA as a single-dose (2 g) treatment of bacterial vaginosis (BV). Secnidazole is characterized by potent in vitro antimicrobial activity against BV-associated pathogens, as well as prolonged terminal elimination half-life and systemic exposure. These characteristics form the basis of effective and safe treatment of BV with a 2-g single-dose secnidazole regimen, which was recently confirmed in double-blind, placebo-controlled clinical trials conducted in the USA. The option to treat BV with single-dose secnidazole not only cures the primary infection but also may diminish risks of serious sequelae of untreated or undertreated infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available